ADHERE-S (NIS Brilique)

Completed

• Conditions: ACS (Acute Coronary Syndrome)

• Registration Number: NCT03444012
• Lead Sponsor: AstraZeneca

Brief Summary

noninterventional study investigating persistence and adherence on ticagrelor in ACS patients in Serbia

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2018-02-09
• Study First Submitted QC: 2018-02-19
• Study First Posted: 2018-02-23
• Study Start: 2018-03-05
• Primary Completion: 2019-08-13
• Study Completion: 2019-08-13
• Status Verified: 2020-07
• Last Update Submitted: 2020-08-05
• Last Update Posted: 2020-08-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 269

Inclusion Criteria

• ≥ 18 years of age
• diagnosed with ACS - STEMI or NSTEMI or unstable angina, invasively or non-invasively treated
• Patients already on treatment with ticagrelor at least for 1 month and no longer than 3 months prior to study initiation. Enrolment in this study must not be trigger for ticagrelor initiation.
• read and signed the Informed Consent Form

Exclusion Criteria

Any contraindications as per approved SmPC of Brilique

• Patients with life-threatening conditions which could disable patients to comply with scheduled visits and/or not able to fill in the patient questionnaires.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
duration (number of days) on ticagrelor therapy in patients with acute coronary syndrome	1 year (12 months)

Trial Locations

Locations (9)

CHC Bezanijska Kosa; 🇷🇸 Belgrade, Serbia

Institute for cardiovascular diseases, Dedinje; 🇷🇸 Belgrade, Serbia

CHC Zvezdara; 🇷🇸 Belgrade, Serbia

Medical Military Academy; 🇷🇸 Belgrade, Serbia

Clinical Center Kragujevac; 🇷🇸 Kragujevac, Serbia

CHC Zemun; 🇷🇸 Belgrade, Serbia

Clinical Center Nis; 🇷🇸 Nis, Serbia

Clinical Center of Serbia; 🇷🇸 Belgrade, Serbia

Institute for cardiovascular diseases of Vojvodina; 🇷🇸 Sremska Kamenica, Serbia